on Moderna, Inc. (NASDAQ:MRNA)
Moderna Secures Approval for RSV Vaccine in Australia
Moderna, Inc. announced the Australian Therapeutic Goods Administration's approval of mRESVIA® (mRNA-1345), an mRNA vaccine targeting respiratory syncytial virus (RSV) in adults over 60. This marks the first mRNA vaccine approval in Australia beyond COVID-19. Stéphane Bancel, CEO of Moderna, emphasized the importance of this milestone in protecting older adults from RSV-related diseases.
RSV presents a significant health burden, particularly for older Australians, with substantial cases recorded during the 2024 winter. The approval follows successful Phase 3 trials involving 37,000 participants over 60. Moderna plans to supply the vaccine from its facility in Melbourne.
mRESVIA is now approved in several regions including the US and EU, with applications pending globally.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Moderna, Inc. news